These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23928345)

  • 41. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries.
    Martinowitz U; Holcomb JB; Pusateri AE; Stein M; Onaca N; Freidman M; Macaitis JM; Castel D; Hedner U; Hess JR
    J Trauma; 2001 Apr; 50(4):721-9. PubMed ID: 11303171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM; Keenan JC; Morton CT; Dries DJ
    Biomed Res Int; 2014; 2014():583794. PubMed ID: 25136597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits.
    Durand M; Godier A; Notet V; Hacquard M; Collignon O; Corbonnois G; Plénat F; Carteaux JP; Lecompte T
    Eur J Anaesthesiol; 2011 Jan; 28(1):51-6. PubMed ID: 20625303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant Factor VIIa Reduces Bleeding after Blunt Liver Injury in a Pig Model of Dilutional Coagulopathy under Severe Hypothermia.
    Spronk HM; Braunschweig T; Rossaint R; Wüst DC; van Oerle R; Lauritzen B; Tolba R; Grottke O
    PLoS One; 2015; 10(6):e0113979. PubMed ID: 26098426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models.
    Ghosh S; Krege W; Doerr B; Mischnik M; Pragst I; Dickneite G; Herzog E
    PLoS One; 2021; 16(10):e0258192. PubMed ID: 34614035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
    Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
    Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activated Factor 7 Versus 4-Factor Prothrombin Complex Concentrate for Critical Bleeding Post-Cardiac Surgery.
    Mehringer SL; Klick Z; Bain J; McNeely EB; Subramanian S; Pass LJ; Drinkwater D; Reddy VS
    Ann Pharmacother; 2018 Jun; 52(6):533-537. PubMed ID: 29332420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
    Körber MK; Langer E; Ziemer S; Perzborn E; Gericke C; Heymann Cv
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):735-40. PubMed ID: 23832064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Thromb J; 2017; 15():6. PubMed ID: 28239301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia.
    Mazzeffi M; Beller J; Strobel R; Norman A; Wisniewski A; Smith J; Fonner CE; McNeil J; Speir A; Singh R; Tang D; Quader M; Yarboro L; Teman N
    J Cardiothorac Vasc Anesth; 2024 Mar; 38(3):660-666. PubMed ID: 38220518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ticagrelor reversal:
    Calmette L; Martin AC; Le Bonniec B; Zlotnik D; Gouin-Thibault I; Bachelot-Loza C; Gaussem P; Godier A
    J Clin Pathol; 2017 Sep; 70(9):733-739. PubMed ID: 28159767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
    Fries D
    Transfusion; 2013 Jan; 53 Suppl 1():91S-95S. PubMed ID: 23301979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. rFVIIa and NN1731 reduce bleeding in hydroxyethyl starch hemodiluted rabbits.
    Lauritzen B; Viuff D; Tranholm M; Ezban M
    J Trauma; 2010 Nov; 69(5):1196-202. PubMed ID: 20032791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.